FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per respons	e 0.5				

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * MCLAUGHLIN JOHN			2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/30/2017					•		r (give title belo		Other (specify b	pelow)	
(Street) PETALUMA, CA 94954			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X. Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City))	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)		(A) or Disposed o (D) (Instr. 3, 4 and 5)			Beneficia	lly Owned Following Transaction(s)		()	Beneficial Ownership
						Code	V	Amou	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common value per	Stock, \$0. share	0001 par	05/30/2017			A		1,036	A	(1)	12,261			D	
Reminder: indirectly.	Report on a	separate line		Derivative Securi	ties A	cquire	Persecontaine fo	ons whained i	n this for splays a c	m are curre	e not req ntly valid	uired to re d OMB co	nformation espond unl ntrol numb	ess	EC 1474 (9- 02)
Security (Instr. 3)	Conversion	3. Transactic Date (Month/Day/	on 3A. Deemed Execution Da any	4. tate, if Transaction Code Year) (Instr. 8)	5. No of Derrised Section (A) Dispose of (I (Ins	5. Number		tions, convertible secur 6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Owners Form of Derivati Security Direct (or Indire	(Instr. 4)
				Code V	(A)	(D)	Date Exer		Expiration Date	Title	Amount or Number of Shares				
Repor	ting O	wners													

Donatha Omas Nasa / Adda	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MCLAUGHLIN JOHN C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954	X					

Signatures

/s/ Robert Miller as attorney-in-fact	06/01/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

